Literature DB >> 17069896

In vitro improvement of a shark IgNAR antibody by Qbeta replicase mutation and ribosome display mimics in vivo affinity maturation.

George Kopsidas1, Anthony S Roberts, Gregory Coia, Victor A Streltsov, Stewart D Nuttall.   

Abstract

We have employed a novel mutagenesis system, which utilizes an error-prone RNA dependent RNA polymerase from Qbeta bacteriophage, to create a diverse library of single domain antibody fragments based on the shark IgNAR antibody isotype. Coupling of these randomly mutated mRNA templates directly to the translating ribosome allowed in vitro selection of affinity matured variants showing enhanced binding to target, the apical membrane antigen 1 (AMA1) from Plasmodium falciparum. One mutation mapping to the IgNAR CDR1 loop was not readily additive to other changes, a result explained by structural analysis of aromatic interactions linking the CDR1, CDR3, and Ig framework regions. This combination appeared also to be counter-selected in experiments, suggesting that in vitro affinity maturation is additionally capable of discriminating against incorrectly produced protein variants. Interestingly, a further mutation was directed to a position in the IgNAR heavy loop 4 which is also specifically targeted during the in vivo shark response to antigen, providing a correlation between natural processes and laboratory-based affinity maturation systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17069896     DOI: 10.1016/j.imlet.2006.09.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

Review 1.  Structural and genetic diversity in antibody repertoires from diverse species.

Authors:  Miguel de los Rios; Michael F Criscitiello; Vaughn V Smider
Journal:  Curr Opin Struct Biol       Date:  2015-07-17       Impact factor: 6.809

2.  Identification of two forms of Q{beta} replicase with different thermal stabilities but identical RNA replication activity.

Authors:  Norikazu Ichihashi; Tomoaki Matsuura; Kazufumi Hosoda; Tetsuya Yomo
Journal:  J Biol Chem       Date:  2010-09-21       Impact factor: 5.157

Review 3.  Ancient species offers contemporary therapeutics: an update on shark VNAR single domain antibody sequences, phage libraries and potential clinical applications.

Authors:  Hejiao English; Jessica Hong; Mitchell Ho
Journal:  Antib Ther       Date:  2020-01-21

4.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Authors:  S J Busfield; M Biondo; M Wong; H S Ramshaw; E M Lee; S Ghosh; H Braley; C Panousis; A W Roberts; S Z He; D Thomas; L Fabri; G Vairo; R B Lock; A F Lopez; A D Nash
Journal:  Leukemia       Date:  2014-04-07       Impact factor: 11.528

5.  Structural insights and biomedical potential of IgNAR scaffolds from sharks.

Authors:  Stefan Zielonka; Martin Empting; Julius Grzeschik; Doreen Könning; Caroline J Barelle; Harald Kolmar
Journal:  MAbs       Date:  2015       Impact factor: 5.857

6.  RNA mutagenesis yields highly diverse mRNA libraries for in vitro protein evolution.

Authors:  George Kopsidas; Rachael K Carman; Emma L Stutt; Anna Raicevic; Anthony S Roberts; Mary-Anne V Siomos; Nada Dobric; Luisa Pontes-Braz; Greg Coia
Journal:  BMC Biotechnol       Date:  2007-04-11       Impact factor: 2.563

7.  Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Authors:  Dae Young Kim; Rebecca To; Hiba Kandalaft; Wen Ding; Henk van Faassen; Yan Luo; Joseph D Schrag; Nadereh St-Amant; Mary Hefford; Tomoko Hirama; John F Kelly; Roger MacKenzie; Jamshid Tanha
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

8.  Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization.

Authors:  Tanya A Camacho-Villegas; María Teresa Mata-González; Walter García-Ubbelohd; Linda Núñez-García; Carolina Elosua; Jorge F Paniagua-Solis; Alexei F Licea-Navarro
Journal:  Mar Drugs       Date:  2018-03-31       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.